Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. Individual who has chronic hepatitis has increased
risk for cirrhosis and liver cancer. In 2017, WHO reports that the estimated number of chronic hepatitis C infection is
71 million globally and approximately 400,000 people die each y ear from hepatitis C, mostly from cirrhosis and
hepatocellular carcinoma. Hepatitis C can be transmitted from blood, from mother to child and through sexual contact.
Approximate 55-85% of infected individuals will develop chronic HCV infection and have a risk of cirrhosis and liver cancer.
Now, doctors can check for hepatitis C in more detailed. Specie of hepatitis’ sub-species can be detected. In addition,
there are more effective antiretroviral drugs. Therefore, effective detection of infected patients will allow more people to access to appropriate treatment.
HCV Ag is a new marker for Hepatitis C
HCV Ag helps in diagnosis of hepatitis C and can be used to diagnose and monitor treatment. This statement follows
the recommendation of WHO 2017 and EASL (European Association for the Study of the Liver) 2016.
Benefits of HCV Ag
• HCV Ag can be detected at around 2 weeks after
infection. It was found before Anti HCV.
• Available for screening, diagnosis, and monitoring
of HCV infection.
• HCV Ag test results were consistent with PCR for
HCV up to 97%
• HCV Ag is used as an alternative test for PCR for HCV
because it is cheaper and shorter turnaround time.
The test should be under the discretion of a physician. | The mentioned test is performed by the laboratory with ISO 15189 certification and lab accreditation.
*This operation schedule is for the test performed at N Health head quarter, Bangkok.
**Above turnaround time does not include logistic time. For BDMS network hospitals, please contact N Health laboratory located at your hospitals.